Skip to main content
 
 
 
MENU
VISIT JANSSEN GLOBAL

EMEA
change location▼

Search
Search

VISIT JANSSEN GLOBAL

Janssen EMEA › Media Center

Media Center

The Media Center is intended to provide resources for media professionals only. It is not intended for use by healthcare professionals, patients or the general public. To access, please confirm that you are an accredited member of the press. I hereby confirm that I am an accredited member of the press
I Agree
Cancel

Press Releases

Jan 18, 2023

Janssen and Global Partners to Discontinue Phase 3 Mosaico HIV Vaccine Clinical Trial 

Jan 03, 2023

Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Dec 16, 2022

Janssen Withdraws Application in European Union Seeking Approval of IMBRUVICA® (ibrutinib) for the Treatment of Patients with Untreated Mantle Cell Lymphoma

Dec 12, 2022

Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

Dec 10, 2022

Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI®▼ (teclistamab) in Combination with DARZALEX® (daratumumab) Subcutaneous (SC) Formulation and Lenalidomide in Relapsed or Refractory Multiple Myeloma

Dec 10, 2022

Janssen Presents New Data for Talquetamab, a GPRC5DxCD3 Bispecific Antibody, Showing Durable Responses in Patients with Heavily Pretreated Multiple Myeloma

View more Press Releases

Media Backgrounders

Neuroscience Backgrounder

Schizophrenia Backgrounder

Waldenström’s Macroglobulinemia (WM)

The Role Of The Immune System In Crohn’s Disease

Stelara MOA infographic

About Crohn’s Disease Backgrounder

VIEW MORE MEDIA BACKGROUNDERS

VIRTUAL ONCOLOGY PRESSROOM

Quick Links

 

Tweets

 
Follow us on Twitter
SUBSCRIBE TO OUR YOUTUBE CHANNEL